Jazz Pharmaceuticals (JAZZ) and Harmony Biosciences (HRMY) have emerged as notable players in the neuroscience space, especially in the sleep disorder segment. Jazz Pharmaceuticals markets multiple neuroscience drugs, including the blockbuster oral sleep disorder drug Xywav and the cannabidiol (CBD) drug Epidiolex. Harmony Biosciences has only one marketed drug in its portfolio, Wakix (pitolisant), which is approved to treat excessive daytime sleepiness (EDS) or cataplexy in narcolepsy patients. Both compan ...